Objective: This systematic review and meta-analysis of randomized controlled trials and retrospective controlled studies aims to evaluate the efficacy and safety of high-dose tranexamic acid (TXA) in spinal correction surgery for adolescent idiopathic scoliosis patients.
Methods: In March 2024, a comprehensive search was conducted in PubMed, Web of Science, Embase, and Cochrane databases to identify randomized controlled trials and retrospective controlled studies comparing the effects of high-dose TXA on blood loss and transfusion requirements during spinal correction surgery.
Results: This meta-analysis included 10 studies encompassing a total of 741 patients. The pooled results indicated that the use of high-dose TXA significantly reduced intraoperative blood loss [weighted mean difference (WMD) = -519.83, 95% CI (-724.74, -314.92), P < 0.00001], transfusion rate [RR = 0.28, 95% CI (0.17, 0.45), P < 0.00001], total blood loss [WMD = -891.09, 95% CI (-1623.92, -158.26), P = 0.02], and postoperative blood loss [WMD = -105.91, 95% CI (-141.29, -70.52), P < 0.00001]. There was no significant difference in operative time [WMD = -18.96, 95% CI (-40.20, 2.28), P = 0.08] and blood loss per segment [WMD = -50.51, 95% CI (-102.19, 1.17), P = 0.06]. Both groups had a comparable incidence of thromboembolic events.
Conclusions: Our meta-analysis suggests that the use of high-dose TXA reduces intraoperative blood loss, transfusion rate, total blood loss, and postoperative blood loss in spinal correction surgery for adolescent idiopathic scoliosis patients. However, there were no significant differences in operative time and blood loss per segment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.wneu.2024.07.203 | DOI Listing |
World Neurosurg
December 2024
Department of Paediatrics, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, India; Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Pune, India.
World Neurosurg
December 2024
Department of Orthopaedics, Lanzhou University Second Hospital, Lanzhou, Gansu, China. Electronic address:
Brachytherapy
December 2024
Department of Radiation Oncology, University of Taxes, Southwestern Medical Center, Dallas, Texas.
Background: Cervical cancer is the second most common cancer among women in Nigeria where, the gap between need for, and access to, radiation therapy including brachytherapy is significant. This report documents the implementation of the first three-dimensional high-dose-rate (3D-HDR) brachytherapy service for cervical cancer in Nigeria.
Purpose: This report details the steps taken to implement the 3D-HDR brachytherapy program, the challenges faced, and the adaptive strategies employed to overcome them.
Curr Oncol
December 2024
Division of Palliative Medicine, Department of Internal Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Cancer-related neuropathic pain (CRNP) is often a significant burden on patients' quality of life. There are limited treatment guidelines for cancer-related neuropathic pain outside of CIPN. Although opioids are considered a third-line treatment option, no consensus exists on which opioid is most effective, either as a single agent or in combination with other medications.
View Article and Find Full Text PDFJ Gynecol Oncol
November 2024
The 3th Ward of Radiotherapy Department, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China.
Objective: To explore the application value of using 3-dimensional (3D) printing (3DP) technology to create individualized vaginal molds for brachytherapy (BT) in high-dose-rate 3D cervical cancer through reverse engineering of needle placement.
Methods: Prospectively, 11 patients with cervical cancer were treated with 3DP-intracavitary/interstitial (IC/IS) BT using 3DP to create individualized vaginal molds. All patients were performed BT after completion of external beam radiotherapy (EBRT).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!